Literature DB >> 10490926

Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.

S N Iyer1, G Gurujeyalakshmi, S N Giri.   

Abstract

This study was undertaken to investigate whether treatment with the antifibrotic drug pirfenidone (PD) down-regulates the bleomycin (BL)-induced overexpression of transforming growth factor (TGF)-beta gene in the lungs. Hamsters were intratracheally instilled with SA or BL (6.5 U/kg/4 ml) under anesthesia. They were fed a diet containing 0.5% PD or the same control diet (CD) without the drug 2 days before and throughout the study. After the animals were sacrificed, their lungs were appropriately processed. The BL treatment elevated the total influx of inflammatory cells, including macrophages, by severalfold at different days in bronchoalveolar lavage fluid (BALF) from hamsters in BL + CD groups, relative to the corresponding SA + CD control groups. Treatment with PD significantly (P </=.05) suppressed the influx of inflammatory cells and macrophages at day 7 in the BL + PD groups, relative to the corresponding BL + CD groups. In addition, the levels of TGF-beta in BALF from hamsters in BL + CD groups were elevated by 2.6- to 4.5-fold at different days, relative to the corresponding SA + CD groups. Treatment with PD significantly (P </=.05) reduced the TGF-beta protein in BALF from BL + PD groups at 14 and 21 days, when compared with the corresponding BL + CD groups. The intratracheal instillation of BL significantly (P </=.05) elevated the TGF-beta mRNA at 7, 14, and 21 days in BL + CD groups, relative to the corresponding SA + CD groups, and treatment with PD significantly (P </=.05) suppressed the TGF-beta gene expression in BL + PD groups at these times, when compared with the corresponding BL + CD groups. Nuclear runoff studies revealed that PD suppressed the BL-induced increase in TGF-beta gene transcription by 33%. It was concluded that one of the mechanisms for antifibrotic effect of PD is its ability to suppress the BL-induced overexpression of TGF-beta gene at the transcriptional level.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490926

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  99 in total

1.  Pirfenidone for diabetic nephropathy.

Authors:  Kumar Sharma; Joachim H Ix; Anna V Mathew; Monique Cho; Axel Pflueger; Stephen R Dunn; Barbara Francos; Shoba Sharma; Bonita Falkner; Tracy A McGowan; Michael Donohue; Satish Ramachandrarao; Ronghui Xu; Fernando C Fervenza; Jeffrey B Kopp
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 2.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging.

Authors:  Na Sun; Isis E Fernandez; Mian Wei; Yin Wu; Michaela Aichler; Oliver Eickelberg; Axel Walch
Journal:  Histochem Cell Biol       Date:  2015-12-08       Impact factor: 4.304

Review 4.  A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays.

Authors:  Phyllis C Leppert; William H Catherino; James H Segars
Journal:  Am J Obstet Gynecol       Date:  2006-04-25       Impact factor: 8.661

Review 5.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

6.  Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis.

Authors:  Avinandan Saha; Preyas J Vaidya; Vinod B Chavhan; Amolkumar Achlerkar; Jörg D Leuppi; Prashant N Chhajed
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

7.  Pirfenidone.

Authors:  Luca Richeldi; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-07       Impact factor: 84.694

8.  Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.

Authors:  Satomi Onoue; Yoshiki Seto; Masashi Kato; Yosuke Aoki; Yoshiki Kojo; Shizuo Yamada
Journal:  Pharm Res       Date:  2013-02-21       Impact factor: 4.200

Review 9.  Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

Review 10.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.